Search

Donanemab

[L50988] It works to reduce amyloid beta plaques and impede the progression of AD.[L50988]

Cefadroxil

Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

Adagrasib

[A187559] Adagrasib targets KRAS^G12C, one of the most common KRAS mutations, at the cysteine 12 residue and inhibits KRAS-dependent signalling. … [L43847] In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRAS^G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic

Sertindole

It is a phenylindole derivative used in the treatment of schizophrenia. … It has once again been approved and should soon be available on the French and Australian market.

Olopatadine

It is a structural analog of [doxepin], which has a minimal anti-allergic activity. … It is currently marketed under several brand names, including Pazeo, Patanase, and Opatanol.

Sipavibart

[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025. … [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell.

Bedaquiline

[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. … [A261866] Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP.

Caplacizumab

Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

Cobalamin

Icotrokinra

It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.